Skip to main content

The use of amisulpride in schizophrenic patients with resistant symptomatology

Background

The purpose of this study was to evaluate the use of the pharmaceutical drug Amisulpride (Solian) in schizophrenic patients with resistant semiology

Materials and methods

The material of this study was 21 patients (17 men and 4 women) who were diagnosed with schizophrenic disorder paranoid type based on DSM-IV, and were recorded with durable symptomatology (delusions, paranoid ideas etc.) even though the continuous issuing of Amisulpride in normal doses (800-1200 mg/daily). In these patients was given Amisulpride in larger doses than the proposed (1600-2000 mg/daily). The evaluation was done with the PANSS scale

Results

After a 30 day time interval and while the continuous issuing of Amisulpride in larger doses was observed considerably reprocess of the resistant symptoms, fact that recorded at the grade alleviation at PANSS scale

Conclusions

Is concluding that the continuous issuing of Amisulpride in larger doses than the normal ones help considerably in obliteration of the durable symptoms of schizophrenia.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dimitrios Kalfas.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Kalfas, D., Markou, S., Gkletsos, A. et al. The use of amisulpride in schizophrenic patients with resistant symptomatology. Ann Gen Psychiatry 9, S135 (2010). https://doi.org/10.1186/1744-859X-9-S1-S135

Download citation

Keywords

  • Public Health
  • Schizophrenia
  • Large Dose
  • Schizophrenic Patient
  • Normal Dose